Evidence map›Paper›PMID 24748976›Full record

ArticleBiomedical reports2014

Characterization of gut microbiota profiles by disease activity in patients with Crohn's disease using data mining analysis of terminal restriction fragment length polymorphisms.

Akira Andoh, Toshio Kobayashi, Hiroyuki Kuzuoka, Tomoyuki Tsujikawa, Yasuo Suzuki, Fumihito Hirai, Toshiyuki Matsui, Shiro Nakamura, Takayuki Matsumoto, Yoshihide Fujiyama

Abstract read
In one paragraph

Article in Biomedical reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Numerical analyses of intestinal microbiota by data mining.Journal of clinical biochemistry and nutrition · 2018
    Review
  10. Article
  11. Psychobiotics and the gut-brain axis: in the pursuit of happiness.Neuropsychiatric disease and treatment · 2015
    Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Akira AndohDivision of Mucosal Immunology, Graduate School of Medicine, Shiga University of Medical Science, Otsu, Shiga 520-2192, Japan.
Toshio KobayashiMiyagi University, Sendai, Miyagi 982-0215, Japan.
Hiroyuki KuzuokaResearch and Development Laboratories, EN Otsuka Pharmaceutical Co., Ltd., Hanamaki, Iwate 025-0312, Japan.
Tomoyuki TsujikawaDepartment of Medicine, Shiga University of Medical Science, Otsu, Shiga 520-2192, Japan.
Yasuo SuzukiDepartment of Internal Medicine, Sakura Medical Center, Toho University, Sakura, Chiba 285-8741, Japan.
Fumihito HiraiDepartment of Gastroenterology, Chikushi Hospital, Fukuoka University, Chikushino, Fukuoka 814-0180, Japan.
Toshiyuki MatsuiDepartment of Gastroenterology, Chikushi Hospital, Fukuoka University, Chikushino, Fukuoka 814-0180, Japan.
Shiro NakamuraDivision of Lower Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Hyogo 663-8131, Japan.
Takayuki MatsumotoDivision of Lower Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Hyogo 663-8131, Japan.
Yoshihide FujiyamaDepartment of Medicine, Shiga University of Medical Science, Otsu, Shiga 520-2192, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The gut microbiota plays a significant role in the pathogenesis of Crohn's disease (CD). In this study, we analyzed the disease activity and associated fecal microbiota profiles in 160 CD patients and 121 healthy individuals. Fecal samples from the CD patients were collected during three different clinical phases, the active (n=66), remission-achieved (n=51) and remission-maintained (n=43) phases. Terminal restriction fragment length polymorphism (T-RFLP) and data mining analysis using the Classification and Regression Tree (C&RT) approach were performed. Data mining provided a decision tree that clearly identified the various subject groups (nodes). The majority of the healthy individuals were divided into Node-5 and Node-8. Healthy subjects comprised 99% of Node-5 (91 of 92) and 84% of Node-8 (21 of 25 subjects). Node-3 was characterized by CD (136 of 160 CD subjects) and was divided into Node-6 and Node-7. Node-6 (n=103) was characterized by subjects in the active phase (n=48; 46%) and remission-achieved phase (n=39; 38%) and Node-7 was characterized by the remission-maintained phase (21 of 37 subjects; 57%). Finally, Node-6 was divided into Node-9 and Node-10. Node-9 (n=78) was characterized by subjects in the active phase (n=43; 55%) and Node-10 (n=25) was characterized by subjects in the remission-maintained phase (n=16; 64%). Differences in the gut microbiota associated with disease activity of CD patients were identified. Thus, data mining analysis appears to be an ideal tool for the characterization of the gut microbiota in inflammatory bowel disease.

Indexed as

data mininginflammatory bowel diseasemicrobiotaterminal restriction fragment length polymorphism

Identifiers

PMID24748976
PMCPMC3990205

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.